Ezetimibe's Effectiveness in HIV Patients
Author Information
Author(s): Matthew T Bennett, Kevin W Johns, Gregory P Bondy
Primary Institution: University of British Columbia
Hypothesis
Does adding ezetimibe to maximally tolerated lipid lowering therapy improve lipid profiles in patients with HIV dyslipidemia?
Conclusion
Ezetimibe is safe and effective in improving lipid profiles in HIV patients on lipid lowering therapy.
Supporting Evidence
- Mean total cholesterol was reduced by 21%.
- Mean LDL was reduced by 35%.
- Mean HDL increased by 8%.
- Mean triglycerides were reduced by 34%.
- Mean Apolipoprotein B100 was reduced by 33%.
- No adverse events occurred.
Takeaway
Ezetimibe helps lower bad cholesterol and raise good cholesterol in people with HIV who are already taking medication to lower their cholesterol.
Methodology
Retrospective analysis of lipid parameters in HIV patients prescribed ezetimibe.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
Small sample size and retrospective design may limit generalizability.
Participant Demographics
33 HIV positive patients, average age 51.4 years, 31 males, with various comorbidities.
Statistical Information
P-Value
p < 0.001 for total cholesterol and LDL reductions; p = 0.038 for HDL increase; p = 0.006 for triglycerides; p = 0.043 for apolipoprotein B100.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website